Market Place
Sourcing Support
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
04 Sep 2024 //
GLOBENEWSWIRE
LIXTE Doses First Patient in Trial for Colorectal Cancer with Pharma Support
26 Aug 2024 //
GLOBENEWSWIRE
First Patient Dosed With LIXTE`s LB-100 In New Colorectal Cancer Trial
26 Aug 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Provides Update On Recent Activities and Developments
19 Aug 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
15 Aug 2024 //
GLOBENEWSWIRE
LIXTE Announces New Colon Cancer Clinical Trial Collaboration
14 Jun 2024 //
GLOBENEWSWIRE
LIXTE`s LB-100 Increases Colon Cancer Cell Recognition By Immune System
06 Jun 2024 //
GLOBENEWSWIRE
LIXTE Names Jan Schellens As Chief Medical Officer
03 Jun 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Holdings Provides Update on Recent Activities
20 May 2024 //
GLOBENEWSWIRE
LIXTE Co-Sponsors Therapeutic Over-Activation Cancer Conference
08 May 2024 //
GLOBENEWSWIRE
New Publication Shows Lb-100 Can Force Cancer Cells to Give up Their Properties
27 Mar 2024 //
GLOBENEWSWIRE
LIXTE Provides Update on LB-100 as a PP2A to Enhance Cancer Treatments
21 Mar 2024 //
GLOBENEWSWIRE
First Patient Dosed with LIXTE`s LB-100 and GSK`s Immunotherapy Dostarlimab-gxly
29 Jan 2024 //
GLOBENEWSWIRE
LIXTE Biot Provides Update on Clinical Progress and Expanding Collaborations
13 Nov 2023 //
GLOBENEWSWIRE
LIXTE, Netherlands Cancer Institute, & Oncode Institute to Expand Collaboration
16 Oct 2023 //
GLOBENEWSWIRE
LIXTE Bio Holdings Announces the Passing of its Founder, John S. Kovach
09 Oct 2023 //
GLOBENEWSWIRE
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
26 Sep 2023 //
GLOBENEWSWIRE
LIXTE Announces Collaborative Trial to Study LIXTE`s LB-100
20 Sep 2023 //
GLOBENEWSWIRE
LIXTE Bio Announces Closing of $3.5 Million Registered Direct Offering
20 Jul 2023 //
GLOBENEWSWIRE
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering
18 Jul 2023 //
GLOBENEWSWIRE
LIXTE BiotechnologyRegains Compliance with Nasdaq Continued Listing
23 Jun 2023 //
GLOBENEWSWIRE
LIXTE & Sarcoma Enroll First Patient in Ph 1b/2 Randomized Trial of Doxorubicin
07 Jun 2023 //
GLOBENEWSWIRE
LIXTE Announces 1-for-10 Reverse Stock Split of its Common Stock
02 Jun 2023 //
GLOBENEWSWIRE
LIXTE Reports First Spanish Site Activated to Begin Accrual of Patients
24 Apr 2023 //
GLOBENEWSWIRE
Lixte Bio Holdings Reports Newly Published Independent Pre-Clinical Research
14 Feb 2023 //
GLOBENEWSWIRE
Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, Lb-100
07 Feb 2023 //
GLOBENEWSWIRE
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase
30 Nov 2022 //
ACCESSWIRE
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OFA PH1B/2 RANDOMIZED TRIAL DOXORUBICIN
13 Oct 2022 //
GLOBENEWSWIRE
Lixte Biotechnology Appoints Bas Van Der Baan To Its Board Of Directors
21 Jun 2022 //
GLOBENEWSWIRE
LIXTE BIOTECH APPOINTS PROFESSOR REN BERNARDS TO ITS BOARD OF DIRECTORS
15 Jun 2022 //
GLOBENEWSWIRE
LIXTE Biotech Announces Closing of $5.8M Registered Direct Offering
15 Apr 2022 //
GLOBENEWSWIRE
LIXTE Bio Reveals Striking Anti-Cancer Activity of LB-100 In Novel Drug Combo
12 Apr 2022 //
GLOBENEWSWIRE
LIXTE Bio Announces $5.8M Registered Direct Offering Priced At-The-Market
12 Apr 2022 //
GLOBENEWSWIRE
Inactivating Mutations in Scaffold Component of PP2A for LB-100
22 Mar 2022 //
GLOBENEWSWIRE
LIXTE Bio to Present at MedInvest Pharmaceutical and Bio Investor Conference
16 Mar 2022 //
GLOBENEWSWIRE
Lixte Biotechnology Announces Filing of First Patent Application for LB-100
12 Jan 2022 //
GLOBENEWSWIRE
Lixte Biotechnology’s LB-100 Reported to Convert Cold Tumors to Hot
05 Jan 2022 //
GLOBENEWSWIRE
Lixte Announces That Enrollment Has Resumed National Cancer Institute`s Trial
22 Nov 2021 //
GLOBENEWSWIRE
Lixte Biotech to Discuss its Collaboration with Leading European Cancer Centers
20 Oct 2021 //
GLOBENEWSWIRE
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute
13 Oct 2021 //
GLOBENEWSWIRE
Lixte LB-100 Shown in Animal Models to Reduce Behavioral Sensitization
17 Aug 2021 //
GLOBENEWSWIRE
LIXTE REPORT THAT PP2A INHIBITOR LB-100 COMBINED ANOTHER INVESTIGATIONAL AGENT
22 Jul 2021 //
GLOBENEWSWIRE
LIXTE REPORT THAT PP2A INHIBITOR LB-100 COMBINED ANOTHER INVESTIGATIONAL AGENT
22 Jul 2021 //
GLOBENEWSWIRE
Lixte Biotechnology Comments on Outside Research Citing LB-100
13 Jul 2021 //
GLOBENEWSWIRE
Lixte Biotechnology to Present Pipeline Data at MoneyShow Virtual Expo
07 Jul 2021 //
GLOBENEWSWIRE
IXICO selected by Cyclerion for new Alzheimer`s disease study
02 Mar 2021 //
PRNEWSWIRE
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
01 Mar 2021 //
GLOBENEWSWIRE
Stock Alert: Lixte Biotechnology Up 55%
26 Feb 2021 //
BUSINESS INSIDER
Lixte and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s LB-100
19 Jan 2021 //
GLOBENEWSWIRE
The Foundation for (FAST) & Lixte Biotech Collaborate For Preclinical Study
18 Aug 2020 //
GLOBENEWSWIRE
